HARMONY BIOSCIENCES HOLDINGS

HRMYNASDAQ

🏆 #1796 by market capEarnings Nov 3US Equity

$39.43▼ $0.09 (−0.23%)

Live

1h▼ 0.1%

24h▼ 0.2%

7d▲ 3.3%

14d▲ 10.1%

30d▲ 11.0%

1y▲ 11.1%

🏦Market Cap

$2.28B

Small Cap

📈Revenue Growth (YoY)

+24.3%

Healthy

📊Gross Margin

75.4%

High

💵FCF Margin

35.0%

Strong

⚖️P/S Ratio

2.4x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $39.21 – $40.08
52-Week Range: $25.52 – $40.87
Volume: $1.83B
Avg Volume: $1.59B
Shares Outstanding: 57.9M
Next Earnings: Oct 21, 2026

Fundamentals Snapshot

Annual Revenue: $868M
Last Q Revenue: $261M
P/E Ratio: 12.5
P/S Ratio: 2.4x
EPS (TTM): $3.09
Dividend Yield: —

Why Investors Own HRMY

✓High-growth profile — revenue up +53.7% YoY with expanding US Equity exposure.
✓Healthy economics — 35% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$868M▲ +50.9% YoY

Gross Margin (TTM)

34.6%▲ +4.5% YoY

Operating Income (TTM)

$265M▲ +50.9% YoY

Free Cash Flow (TTM)

$103M▲ +50.9% YoY

About HARMONY BIOSCIENCES HOLDINGS

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

🦦